Egetis Therapeutics AB (publ)

EGTX · Nasdaq Stockholm · Healthcare

9.18SEK −2.8%last day

Price as of 2 October 2026

The price over the past year, with dividends: +65.1%

Performance

1 month

+17.1%

1 year

+65.1%

3 years, per year

+27.9%

5 years, per year

+11.8%

Largest fall, 3 years

−67.0%

Below the peak now

−82.7%

Volatility, 1 year

58.7%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

8.3

Dividend yield

0.0%

Return on equity

−84.2%

Net margin

−74.4%

Market value

410 m USD

Quality, value and trend

Where Egetis Therapeutics stands against every Nordic stock today. 100 is best.

Quality59

Profitability and a sound balance sheet over time. Better than 59% of Nordic stocks.

Value3

The price measured against earnings, assets and cash flow. Better than 3% of Nordic stocks.

Trend96

The price development over the past year. Better than 96% of Nordic stocks.

Combined52

Quality, value and trend together. Better than 52% of Nordic stocks.

About Egetis Therapeutics

Egetis Therapeutics AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 56 employees.

Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis